Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients

Inclusion Criteria: 1. Male or female subjects aged 18 or older 2. Subjects with a clinical diagnosis of AD according to the Hanifin and Rajka Criteria by a board certified/eligible dermatologist 3. Subjects with IGA score 3 or 4 corresponding to moderate to severe AD at screening and baseline visits Exclusion Criteria: 1. Subjects who had topical treatment with corticosteroids within 1 week before randomization 2. Subjects who had systemic treatment with corticosteroids or cyclosporine or other immunosuppressive treatment within 4 weeks before randomization 3. Subjects who had ultraviolet irradiation (including photopheresis) within 4 weeks before screening 4. Subjects who participated in another drug trial within 4 weeks before screening